

XI SIMPOSIO INTERNACIONAL  
**CÁNCER DE MAMA  
DE SANTIAGO 2018**

CENTRO PARQUE - 18 AL 20 DE ABRIL - SANTIAGO - CHILE



**PROGRAM**

# CÁNCER DE MAMA DE SANTIAGO 2018

## THIRD DRAFT XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM EDUCATIONAL PRE SYMPOSIUM MEETINGS

### Wednesday April 18th, 2018

08:00 - 08:30 Registration

08:00 - 12:00 **NEW ADVANCES IN RECONSTRUCTIVE SURGERY**

08:30 - 08:40 Welcome and Introduction.

#### **Breast reconstruction and radiotherapy. Alternatives for breast reconstruction in irradiated tissue.**

08:40 - 09:10 Plenary Session: Immediate breast reconstruction in previously irradiated breast.

09:10 - 09:25 Radiotherapy over implant.

09:25 - 09:40 Radiotherapy over tissue expander.

09:40 - 10:10 Delayed breast reconstruction after radiotherapy: planning the alternatives.

09:40 - 09:55 Using flaps.

09:55 - 10:10 Using implants.

10:10 - 10:40 Coffee break

#### **Breast Reconstruction using ADMs**

10:40 - 11:00 The evolution of breast reconstruction, from sub-pectoral to pre-pectoral.

11:00 - 11:20 Early outcomes in submuscular versus prepectoral ADM assisted breast reconstruction.

11:20 - 11:40 Early outcomes in cost-effectiveness and functionality in pre-pectoral ADM covered implant versus sub-muscular breast reconstruction.

11:40 - 12:00 Pre-pectoral breast reconstruction. How to avoid complications?

12:00 - 12:20 Q&A

### Wednesday April 18, 2018 (afternoon)

#### **THE PENDING CHALLENGES OF DCIS**

13:30 - 13:50 Is over-diagnosis a problem?

13:50 - 14:10 Active surveillance/de-escalation of therapy approach for low risk DCIS and the importance of margins

14:10 - 14:30 Radiotherapy for DCIS.

#### **HOW TO SUPPORT OUR SURVIVING PATIENTS**

14:35 - 14:55 The emotional and sexual problems of breast cancer survivors.

14:55 - 15:15 How to manage late side effects in surviving patients, including life style.

15:15 - 15:35 Prevention of chemotherapy induced alopecia and potential role of cooling caps.

15:35 - 16:00 Coffee break

# CÁNCER DE MAMA DE SANTIAGO 2018

## **RADIOTHERAPY CONTROVERSIES**

- 16:00 - 16:20 Accelerated Partial breast irradiation: Intra, pre-or post-surgery.
- 16:20 - 16:40 Radiotherapy and breast reconstruction.
- 16:40 - 17:00 State of the Art in Hyper-fractionated radiotherapy schedules.

## **ADVANCES IN BREAST RADIOLOGY**

- 17:00 - 17:20 Limitations of Breast MRI and how to address them.
- 17:20 - 17:40 MRI as a biomarker for diagnostic and prognostic factors.
- 17:40 - 18:00 MRI for screening purposes: ultrashort enhanced protocols or DWI only?
- 18:00 - 19:30 Images work-shop (clinical cases session focused on MRI)

## **XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM**

- 08:00 - 18:00 Registration

### **Thursday April 19th, 2018 (MORNING)**

- 08:30 - 08:40 Opening remarks and welcome

## **WHAT HAVE WE LEARNED FROM NEO-ADJUVANT TREATMENT?**

- 08:40 - 09:00 The benefits of neo-adjuvant therapy according to molecular subtypes.
- 09:00 - 09:20 Neo-adjuvant endocrine treatment: How to select the appropriate patient and how to evaluate response.
- 09:30 - 10:15 Submitted Papers (10 minutes for presentation 5 minutes for Q&A)
- 10:15 - 10:35 MRI in the assessment of neo-adjuvant treatment: response assessment and impact on treatment.
- 10:40 - 11:00 Coffee break
- 11:00 - 11:20 Is surgery of the breast & the axilla mandatory in complete responders to neo-adjuvant treatment?
- 11:20 - 11:40 Radiotherapy after neo-adjuvant treatment.
- 11:40 - 12:00 Adjuvant medical treatment after neo-adjuvant treatment. For whom and with what drugs?
- 12:05 - 13:05 Clinical Cases Discussion (loco-regional)
- 13:05 - 14:05 Industry Symposium
- 14:05 - 14:30 LUNCH TIME

# CÁNCER DE MAMA DE SANTIAGO 2018

## Thursday April 19, 2018 (AFTERNOON)

### OVERCOMING ENDOCRINE RESISTANCE

- 14:30 - 15:00 Palbociclib, rivociclib or amebaciclib: Are all the same? Mechanisms of action and clinical results.
- 15:00 - 15:20 When and whom benefit from the use of everolimus or other PIK3CA inhibitors?
- 15:20 - 15:40 SERMs, SERDs, SSH for the management of endocrine sensitive metastatic breast cancer: How do they fit in the same patient?
- 15:40 - 16:00 Coffee break

### ESCALATING AND DE-ESCALATING TREATMENT INTENSITY

- 16:00 - 16:20 Role of the pathologist for breast cancer treatment: de-escalation and escalation of therapy.
- 16:20 - 16:40 Molecular platforms. Utility and assay comparison.
- 16:40 - 17:10 Submitted papers
- 17:10 - 17:40 Endocrine therapy: 10 years or more for all ER/PgR positive patients? Or Less than 10 years for some of them?
- 17:40 - 18:00 Which patients benefit from axillary dissection?
- 18:00 - 18:20 Which patients do not benefit from radiotherapy?

## Friday, April 20th (MORNING)

### FACING PROBLEMS OF VERY YOUNG PATIENTS WITH BREAST CANCER

- 08:15 - 08:35 Fertility preservation for women with or at risk of breast cancer: For mutation carriers, for women with breast cancer diagnoses.
- 08:35 - 08:55 What to do with tamoxifen in women who desire pregnancy.
- 09:00 - 09:20 Role of ovary suppression in the adjuvant management of hormone receptor positive HER-2 negative very young patients.
- 0940 - 10:00 Role of adjuvant chemotherapy for hormone receptor positive HER-2 negative very young patients
- 10:00 - 10:20 Submitted papers
- 10:20 - 10:40 Coffee Break

### METASTATIC AND RECURRENT DISEASE

- 10:40 - 11:00 When to introduce supportive care in advanced breast cancer.
- 11:00 - 11:20 Personalized medicine in breast cancer: The role of next generation sequencing.
- 11:20 - 11:40 PARP inhibitors: Only useful for triple negative disease? Clinical data and future perspectives.
- 11:40 - 12:00 CDK4/CDK6 for HER-2 positive and triple negative disease: State of the research.
- 12:00 - 13:00 Clinical cases Discussion (Advanced Disease)
- 13:00 - 14:00 Industry Symposium and Lunch Time

# CÁNCER DE MAMA DE SANTIAGO 2018

## Friday April 20th, 2018 (AFTERNOON)

- 14:30 - 14:50 New data and new drugs for HER-2 disease.
- 14:50 - 15:10 Is it clinically useful to classify triple negative disease and what is the best classification?
- 15:10 - 15:30 Immune therapy for triple negative breast cancer.
- 15:30 - 15:50 Immune therapy: The future for breast cancer?
- 15:50 - 16:20 Coffee Break
- 16:20 - 16:40 Management of local recurrence after conservative surgery. Is mastectomy mandatory?
- 16:40 - 17:00 How to manage the systemic treatment after loco-regional recurrence?
- 17:00 - 17:20 Role of surgery in the management of oligo-metastatic breast cancer.  
Does the molecular sub-type matter?